Who are Oral Anticoagulant, Direct-Acting's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Direct-acting oral anticoagulation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-anticoagulant-direct-acting.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Oral Anticoagulant, Direct-Acting — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Anticoagulant, Direct-Acting (Oral Anticoagulant, Direct-Acting) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting oral anticoagulant (DOAC). Area: Cardiovascular.

phase 3 Direct-acting oral anticoagulant (DOAC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Oral Anticoagulant, Direct-Acting (Oral Anticoagulant, Direct-Acting) — Assistance Publique - Hôpitaux de Paris. Direct-acting oral anticoagulants inhibit specific clotting factors (typically Factor Xa or thrombin) to prevent blood clot formation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral Anticoagulant, Direct-Acting TARGET	Oral Anticoagulant, Direct-Acting	Assistance Publique - Hôpitaux de Paris	phase 3	Direct-acting oral anticoagulant (DOAC)
Direct-acting oral anticoagulation	Direct-acting oral anticoagulation	Hospital Universitario La Fe	marketed	Direct-acting oral anticoagulant (DOAC)	Factor IIa or Factor Xa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting oral anticoagulant (DOAC) class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Hospital Universitario La Fe · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Anticoagulant, Direct-Acting — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-anticoagulant-direct-acting. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab